HealthCare Global Enterprises Ltd. HCG
NSE · India · Health Services
INR 668.75+2.70 (+0.41%)
Market closed· · INR · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · INR · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
HealthCare Global Enterprises (HCG), Bengaluru, has begun treating cancer patients using Karnataka's first Elekta Unity MR-Linac. With this milestone, HCG opens up access to MR-guided adaptive radiation therapy for patients across Karnataka and neighbouring regions, bringing one of the most advanced approaches in radiation oncology closer to those who need it.
Company reports 13% YoY revenue increase to INR 6,951 million, with adjusted EBITDA up 20% and a confident path toward 24-25% long-term margins.
HealthCare Global Enterprises Ltd (NSE:HCG) reports robust FY26 growth with strategic expansions, despite facing challenges from low-margin business reductions and geopolitical impacts.
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.